Research

CELLTRION INC (068270 KS)

Since 2010, Celltrion has generated 98% of its sales from its sister company, Celltrion Healthcare, which has been unable to sell 55% of the product that it’s bought. Celltrion Healthcare appears to have been established to buy unapproved drugs from Celltrion. It is highly unlikely that an outside third party would have bought these drugs, and we question the economic substance of these past transactions for Healthcare. We think Celltrion’s profits are significantly overstated, by as much as two-thirds in 9M17, owing to continued channel stuffing at Healthcare and the capitalisation of R&D costs. We therefore apply a 50% discount…
Read more ›

Log In

Insights

TREASURY WINE ESTATES (TWE AU)

Full-year results allay concerns…somewhat

Nigel Stevenson · 16 August 2019

Treasury Wine’s full-year results undoubtedly showed a major improvement in operating cash flow, as receivables declined from elevated levels. While channel-stuffing cannot be ruled out, there is limited evidence of this in the latest financials. Our concerns have been somewhat allayed, although questions remain regarding earnings quality. The direct gains from acquisition accounting appear to have wound down, but we suspect there could be some lagging profit benefits from the sale of other held-back inventory. We maintain our AVOID recommendation given the ongoing uncertainty over earnings quality. GET PDF

SHORT-SELLERS

Blue Orca attacks Ausnutria

Gillem Tulloch · 15 August 2019

In the 8th short-seller attack on Hong Kong listed companies this year, Blue Orca alleges that Ausnutria has been faking sales and profits. The company’s shares are suspended pending a rebuttal from management. It is sometimes possible to demonstrate that a company’s financials do not reflect the allegations, but not here. The company shows similar financial traits to past frauds, and these have become more pronounced over the past two years. Ausnutria’s unusual corporate structure, with production assets in Europe and sales in China, might help explain some of these traits. The best shareholders can hope for is a comprehensive…
Read more ›

TREASURY WINE (TWE AU)

Disappointing vintage

Nigel Stevenson · 7 August 2019

Treasury Wine Estates (TWE) may have inflated profits by up to 50% over the last two years through the use of acquisition accounting to write-down inventories and establish other liabilities. Weak operating cash flow with a widening divergence from cash profits raises additional concerns that profits are being manipulated. Tell-tale signs include rising receivables and inventories which suggest possible channel-stuffing and deferral of overheads. The winding down of benefits from acquisition accounting may have left a hole in earnings; if we are correct, there is 35% downside to A$10.60/share. We currently recommend investors AVOID the stock but poor forthcoming results…
Read more ›

Free Newsletter

GET OUR FREE NEWSLETTER

Input your email address below to sign-up to our free newsletter.